Ad Header



The Pulse of the Pharmaceutical Industry

U.S. FDA allows 23andMe to sell test for 3 mutations of breast cancer gene

Written by: | | Dated: Tuesday, March 6th, 2018


The U.S. Food and Drug Administration on Tuesday allowed genetic testing company 23andMe to market directly to consumers its test that will help assess three mutations in a common type of breast cancer gene.

The drug regulator said the test, which work by analyzing DNA collected from saliva samples, provides genetic risk information but cannot determine a person’s overall risk of developing a disease or condition.

The test detects only three out of more than 1,000 known BRCA mutations and are not the most common ones in the general population, the drug regulator said.

BRCA mutations account for about 50 percent of hereditary breast cancers and up to 65 percent of those who inherit the mutations will develop breast cancer.

The regulator said it reviewed data for the company’s test under a regulatory pathway for low-to-moderate risk devices that are not equivalent to an already marketed device.

The agency also set a condition known as special controls, clarifying its expectations for assuring test accuracy and reliability.


(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Arun Koyyur)


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!


Ad Right Bottom